After decades with no disease-modifying drug, 20242026 finally delivered the first targeted therapies: Novartis ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&Js nipocalimab was positive in the Phase 2 DAHLIAS trial ( The Lancet )
Decramer M, Rutten-van Mlken M, Dekhuijzen PN, Troosters T, van Herwaarden C, et al: Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial
Cells were lysed at 4 C in a radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime Biotechnology)
Furthermore, although some studies report improvements in liver function markers, there is no conclusive evidence that silymarin significantly enhances survival rates in severe liver conditions such as cirrhosis (10)
(2011) has investigated the mechanism of psoriasis focusing on miRNAs since the involvement of miRNAs in skin development has been reported in mouse model (Yi et al., 2006)
